Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1979 1
1986 1
1991 1
1993 1
1998 1
1999 1
2002 1
2004 1
2005 2
2006 1
2009 3
2010 4
2011 4
2012 8
2013 9
2014 27
2015 15
2016 18
2017 11
2018 11
2019 12
2020 12
2021 22
2022 28
2023 30
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

194 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, Verslype C, Bouattour M, Park JO, Barajas O, Pelzer U, Valle JW, Yu L, Malhotra U, Siegel AB, Edeline J, Vogel A; KEYNOTE-966 Investigators. Kelley RK, et al. Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16. Lancet. 2023. PMID: 37075781 Clinical Trial.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
Bone marrow involvement in breast cancer.
Sütcüoğlu O, Özdemir N, Yazıcı O, Özet A. Sütcüoğlu O, et al. Among authors: yazici o. Curr Probl Cancer. 2022 Feb;46(1):100785. doi: 10.1016/j.currproblcancer.2021.100785. Epub 2021 Aug 15. Curr Probl Cancer. 2022. PMID: 34417058 No abstract available.
Thirty-day mortality rates after immunotherapy initiation.
Sütcüoğlu O, İlhan A, Tacar SY, Güven DC, Uçar G, Karadurmuş N, Yıldız F, Eraslan E, Uncu D, Tural D, Üner A, Günel N, Özdemir N, Kılıçkap S, Öksüzoğlu ÖB, Özet A, Yazıcı O. Sütcüoğlu O, et al. Among authors: yazici o. Immunotherapy. 2021 Dec;13(17):1419-1426. doi: 10.2217/imt-2021-0082. Epub 2021 Oct 22. Immunotherapy. 2021. PMID: 34676791
Unipolar mania: a distinct entity?
Yazıcı O. Yazıcı O. J Affect Disord. 2014 Jan;152-154:52-6. doi: 10.1016/j.jad.2013.10.005. Epub 2013 Oct 22. J Affect Disord. 2014. PMID: 24210629 Review.
Major and minor salivary gland cancers: A multicenter retrospective study.
Hacioglu MB, Erdogan B, Bardakcı M, Algın E, Gulbagcı B, Hacibekiroglu I, Hamdard J, Olmez OF, Akkus H, Oksuzoglu B, Goksu SS, Dae SA, Sumbul AT, Ugraklı M, Karaagac M, Sahin E, Cabuk D, Ozer O, Yavuzsen T, Arıkan R, Köstek O, Atcı MM, Sakin A, Deligonul A, Bayır D, Dincer M, Unsal O, Yazıcı O, Zeynelgil E, Gulmez A, Harputluoglu H, Erol C, Sendur MAN, Aytekin A, Akagunduz B, Oner I, Er O, Oztosun B, Gumus M, Selçukbiricik F, Aykan MB, Karadurmus N, Degerli E, Demirci NS, Turkmen E, Şakalar T, Secmeler S, Tanrıverdi O, Alkan A, Kemal Y, Cil I, Unal C, Iriagaç Y, Alan O, Balli S, Urun Y, Ozcan E, Turhal NS, Cicin I. Hacioglu MB, et al. Among authors: yazici o. Head Neck. 2023 Jul;45(7):1643-1653. doi: 10.1002/hed.27376. Epub 2023 Apr 21. Head Neck. 2023. PMID: 37084179
Brigatinib-induced tuberculosis reactivation: A case report.
Keş V, Sütcüoğlu O, Gürler F, Yazıcı O, Özet A. Keş V, et al. Among authors: yazici o. Curr Probl Cancer. 2021 Dec;45(6):100738. doi: 10.1016/j.currproblcancer.2021.100738. Epub 2021 Apr 10. Curr Probl Cancer. 2021. PMID: 33867154
Niraparib-induced pure red cell aplasia.
Bir Yücel K, Yıldız S, Sütcüoglu O, Güvercin FS, Uyar Göçün P, Özdemir N, Yazıcı O, Özet A. Bir Yücel K, et al. Among authors: yazici o. J Oncol Pharm Pract. 2024 Jan;30(1):210-214. doi: 10.1177/10781552231197808. Epub 2023 Aug 29. J Oncol Pharm Pract. 2024. PMID: 37642988
Combination therapies in non-clear-cell renal cell carcinoma.
Aslan V, Özdemir N, Yazıcı O, Özet A. Aslan V, et al. Among authors: yazici o. Lancet Oncol. 2023 Oct;24(10):e401. doi: 10.1016/S1470-2045(23)00393-5. Lancet Oncol. 2023. PMID: 37797639 No abstract available.
194 results